ArticleJournal of endocrinological investigation2015
Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniopharyngioma and non-functioning pituitary adenoma.
Article in Journal of endocrinological investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: an updated systematic review and meta-analysis.Pituitary · 2024Pooled it
- Children with craniopharyngioma resection had better response to recombinant human growth hormone therapy than those with idiopathic short stature.Frontiers in endocrinology · 2026Observational
- Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group.Reviews in endocrine & metabolic disorders · 2025Review
- Growth Hormone Replacement in Craniopharyngioma: Analysis of the Hypopituitary Control and Complications Study (HypoCCS).Journal of the Endocrine Society · 2025Article
- Long-term outcome of childhood and adolescent patients with craniopharyngiomas: a single center retrospective experience.BMC cancer · 2024Article
- Long-Term Safety of Growth Hormone Deficiency Treatment in Cancer and Sellar Tumors Adult Survivors: Is There a Role of GH Therapy on the Neoplastic Risk?Journal of clinical medicine · 2023Review
- Blood Lipid Disorders in Post-Operative Craniopharyngioma Children and Adolescents and the Improvement with Recombinant Human Growth Hormone Replacement.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Article
- Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.Pituitary · 2022Review
- Metabolic syndrome as a common comorbidity in adults with hypothalamic dysfunction.Frontiers in endocrinology · 2022Article
- Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience.Frontiers in neurology · 2022Article
- Review
- Preoperative BMI Predicts Postoperative Weight Gain in Adult-onset Craniopharyngioma.The Journal of clinical endocrinology and metabolism · 2021Article
- GH Deficiency and Replacement Therapy in Hypopituitarism: Insight Into the Relationships With Other Hypothalamic-Pituitary Axes.Frontiers in endocrinology · 2021Review
- Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma.Endocrine · 2017Article
- Sensitivity of various body indices and visceral adiposity index in predicting metabolic syndrome among Chinese patients with adult growth hormone deficiency.Journal of endocrinological investigation · 2017Article
- Long-term safety and efficacy of OmnitropeJournal of endocrinological investigation · 2017Observational
- Review
- Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity.Current opinion in endocrinology, diabetes, and obesity · 2016Review
- Craniopharyngioma in Children: Long-term Outcomes.Neurologia medico-chirurgica · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdult patients operated for craniopharyngioma develop more frequently GH deficiency (GHD) than patients operated for non-functioning pituitary adenoma (NFPA). The aim of the study was to compare both short- (1 year) and long-term (5 years) effects of rhGH in 38 GHD adult patients (19 operated for Craniopharyngioma (CP) and 19 for NFPA).
methodsIGF-I levels, body composition (BF%), BMI, lipid profile and glucose homeostasis were evaluated in all patients. Pituitary MRI was performed at baseline and during follow-up, as needed.
resultsAt baseline no difference between the two groups was observed, apart from a higher prevalence of diabetes insipidus in CP patients (79 vs 21%). After 12 months, IGF-I SDS normalized and BF% significantly decreased only in the NFPA group. During long-term treatment, decrease in BF% and improvement in lipid profile shown by reduction in total- and LDL-cholesterol were present in NFPA group only, while increase in insulin levels and HbA1c and decrease of QUICKI were observed in CP patients only. Accordingly, after long-term therapy, the prevalence of metabolic syndrome (MS) was significantly higher in CP than in NFPA group (37% in CP and in 5% in NFPA group; p < 0.05).
conclusionThe present data suggest that CP patients are less sensitive to the positive rhGH effects on lipid profile and BF% and more prone to insulin sensitivity worsening than NFPA patients, resulting in increased prevalence of MS in CP only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.